Olaparib has recently been approved for ovarian cancer therapy by the FDA (in 4th line) and European commission (platinum sensitive) to treat patients with ovarian cancer resulting from hereditary BRCA1 or BRCA2 mutations. Here, BRCA2 is linked to ovarian carcinoma.